Acceleron Pharma Inc. found itself in an enviable position considering the phase II DART study of dalantercept plus Inlyta (axitinib, Pfizer Inc.) missed its primary endpoint in advanced renal cell carcinoma (RCC). Instead of rocking the company's shares (NASDAQ:XLRN), the trial failure and decision to halt development of dalantercept seemed to allay concerns that the asset was a distraction from the company's lead program, luspatercept, partnered with Celgene Corp. Read More

Squandering much of what could have been a good opportunity to better understand the pricing of prescription drugs, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee reverted to political bickering over repeal of the Affordable Care Act (ACA) in the first of a series of three hearings billed as a bipartisan fact-finding into the who, what and why of drug prices. Read More

SAN DIEGO – A pair of clinical trial presentations at the American Diabetes Association (ADA) 77th Scientific Sessions on Monday, both with simultaneous publications in The New England Journal of Medicine, established the cardiovascular risk of two already-approved diabetes drugs. Read More

SAN DIEGO – Given the high burden of type 1 diabetes with decades of insulin shots as well as renal and cardiovascular complications associated with the disease, preventing or even just delaying the onset of type 1 diabetes has been a long-term focus of researchers. Read More

A new study by Japanese researchers has shown how the loss of a key mitochondrial protein facilitates progression of Parkinson's disease (PD), identifying a new therapeutic target and hence the potential for the discovery and development of new PD treatments. Read More

SHANGHAI – Inventisbio Inc., of Shanghai, has emerged from stealth, nabbing $19 million in series B financing from health care venture financiers Orbimed and Lilly Asia Ventures (LAV). Founded in 2015, Inventisbio has a pipeline of four small-molecule preclinical drug candidates for cancer and gout. Read More

The National Institute for Health and Care Excellence has published its final appraisal determination recommending Kyprolis (carfilzomib, Amgen Inc.) in combination with dexamethasone as an option for treating adults with relapsed multiple myeloma (RMM) who have received one prior therapy that does not include Velcade (bortezomib, Takeda Oncology Co.). Read More

Aimmune Therapeutics Inc., of Brisbane, Calif., said in the ongoing phase III PALISADE trial of AR-101, an investigational biologic oral immunotherapy for desensitization of patients with peanut allergy, more than 97 percent of patients currently on study have completed up-dosing. Read More